Innoviva/$INVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Innoviva
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Ticker
$INVA
Sector
Primary listing
Employees
159
Headquarters
Website
Innoviva Metrics
BasicAdvanced
$1.7B
6.79
$3.30
0.42
-
Price and volume
Market cap
$1.7B
Beta
0.42
52-week high
$25.15
52-week low
$16.52
Average daily volume
808K
Financial strength
Current ratio
14.639
Quick ratio
13.28
Long term debt to equity
27.515
Total debt to equity
28.243
Interest coverage (TTM)
10.10%
Profitability
EBITDA (TTM)
194.991
Gross margin (TTM)
74.94%
Net profit margin (TTM)
65.92%
Operating margin (TTM)
40.99%
Effective tax rate (TTM)
17.04%
Revenue per employee (TTM)
$2,590,000
Management effectiveness
Return on assets (TTM)
7.18%
Return on equity (TTM)
29.09%
Valuation
Price to earnings (TTM)
6.791
Price to revenue (TTM)
3.673
Price to book
1.43
Price to tangible book (TTM)
1.72
Price to free cash flow (TTM)
8.105
Free cash flow yield (TTM)
12.34%
Free cash flow per share (TTM)
2.766
Growth
Revenue change (TTM)
14.67%
Earnings per share change (TTM)
811.83%
3-year revenue growth (CAGR)
7.47%
10-year revenue growth (CAGR)
22.52%
3-year earnings per share growth (CAGR)
11.71%
10-year earnings per share growth (CAGR)
35.13%
What the Analysts think about Innoviva
Analyst ratings (Buy, Hold, Sell) for Innoviva stock.
Innoviva Financial Performance
Revenues and expenses
Innoviva Earnings Performance
Company profitability
Innoviva News
AllArticlesVideos
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report
Business Wire·2 days ago
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Business Wire·3 weeks ago
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
MarketBeat·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Innoviva stock?
Innoviva (INVA) has a market cap of $1.7B as of March 12, 2026.
What is the P/E ratio for Innoviva stock?
The price to earnings (P/E) ratio for Innoviva (INVA) stock is 6.79 as of March 12, 2026.
Does Innoviva stock pay dividends?
No, Innoviva (INVA) stock does not pay dividends to its shareholders as of March 12, 2026.
When is the next Innoviva dividend payment date?
Innoviva (INVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Innoviva?
Innoviva (INVA) has a beta rating of 0.42. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.